A new clinical trial focusing on skin autofluorescence as a biomarker for advanced glycation end products (AGEs) in patients with rheumatic diseases has been announced. The trial, sponsored by Bursa City Hospital, seeks to uncover insights into conditions such as rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, and other connective tissue disorders. As of January 10, 2026, enrollment has not yet begun.
What is this trial about?
This clinical trial aims to explore the potential of skin autofluorescence as a diagnostic tool for assessing AGEs in patients suffering from various rheumatic conditions. AGEs are harmful compounds formed from the reaction of sugars with proteins and lipids, often implicated in chronic diseases. Researchers are investigating whether this non-invasive method can provide critical diagnostic or prognostic information.
Target diseases include:
- Rheumatoid Arthritis (RA)
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Reactive Arthritis (ReA)
- Crystal Arthropathies
- Connective Tissue Diseases
- Familial Mediterranean Fever (FMF)
By focusing on systemic inflammation and oxidative stress associated with AGEs accumulation, the trial seeks to provide data that could refine diagnostic pathways or therapeutic approaches.
What are advanced glycation end products?
AGEs are molecules formed through non-enzymatic reactions between sugars and proteins or lipids. They accumulate naturally over time but can increase significantly in individuals with chronic inflammation or metabolic disorders. AGEs are known to play a role in the pathogenesis of various diseases, including diabetes, cardiovascular condition, and inflammatory disorders such as rheumatoid arthritis.
Excessive AGEs accumulation can impair molecular functions, leading to cellular damage and systemic inflammation. Their presence in tissues can serve as an indicator of disease severity and progression.
How can skin autofluorescence aid diagnosis?
This trial is set to use skin autofluorescence as a marker to measure AGE levels. The technique involves the use of medical devices designed to detect and quantify AGEs by analyzing skin fluorescence properties. Early findings suggest that skin autofluorescence could be a reliable, non-invasive biomarker for assessing oxidative stress and inflammation levels.
Compared to traditional blood tests or tissue sampling, this method offers a quicker, less invasive diagnostic option which may aid in monitoring disease progression and therapeutic efficacy.
Future implications for medical devices
The clinical study could set the stage for integrating skin autofluorescence measuring devices into routine clinical practice for rheumatic conditions and beyond. If successful, these devices may provide clinicians with rapid insights into disease severity, prognosis, and personalized treatment pathways.
Medical device manufacturers will need to adhere to strict regulatory standards when developing similar devices, as evidence-based performance and safety data will remain key under frameworks such as the EU Medical Device Regulation (EU MDR).
This study could influence design criteria for next-generation diagnostic devices, emphasizing accuracy, ease of use, and applicability to diverse patient populations.
FAQ
1. What diseases are being studied?
Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Connective Tissue Diseases, Crystal Arthropathies, and Familial Mediterranean Fever.
2. Why are AGEs important in rheumatic diseases?
AGEs contribute to inflammation and tissue damage, impacting disease severity and progression.
3. How does skin autofluorescence work?
It measures tissue fluorescence induced by AGEs accumulation, providing a potential biomarker for stress and inflammation.
Conclusion
The new trial sponsored by Bursa City Hospital could reshape diagnostics in rheumatic disease management. Skin autofluorescence holds promise as a non-invasive biomarker for oxidative stress and AGEs levels, offering significant clinical implications if successful.
Disclaimer
This article is intended for informational purposes only and does not constitute legal or clinical advice. Professionals should consult regulatory frameworks and clinical guidelines.
Announcement Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07329556?term=medical+device